Mark M Foreman

US Patent:

6630478, Oct 7, 2003

Filed:

Jul 6, 2001

Appl. No.:

09/899901

Inventors:

Jack Diamond - Hamilton, CA
Alvin J. Glasky - Tustin CA
Mark M. Foreman - Tustin CA

Assignee:

NeoTherapeutics, Inc. - Irvine CA

International Classification:

A61K 3152

US Classification:

514262

Abstract:

A method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of N-4-carboxaphenyl-3-(6-oxohydropurin-9-yl)propananide AIT-082, is disclosed. Peripheral nerve sprouting can be induced through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy is associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine.

US Patent:

6759427, Jul 6, 2004

Filed:

Apr 20, 2001

Appl. No.:

09/839289

Inventors:

David B. Fick - Newport Beach CA
Mark M. Foreman - Tustin CA
Alvin J. Glasky - Tustin CA

Assignee:

Spectrum Pharmaceuticals, Inc. - Irvine CA

International Classification:

A61K 31405

US Classification:

514415, 514427, 51425409, 514678, 548510, 548550, 548469

Abstract:

A tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y )-D, where Y can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

US Patent:

6770638, Aug 3, 2004

Filed:

Jul 30, 2002

Appl. No.:

10/209451

Inventors:

David B. Fick - Newport Beach CA
Mark M. Foreman - Tustin CA
Alvin J. Glasky - Mission Viejo CA
David R. Helton - Mission Viejo CA

Assignee:

Spectrum Pharmaceuticals, Inc. - Irvine CA

International Classification:

A61K 3133

US Classification:

514183, 51425409, 548416, 548469, 548452, 548509, 548550, 544358, 544373, 544402

Abstract:

Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.

US Patent:

20020156277, Oct 24, 2002

Filed:

Apr 20, 2001

Appl. No.:

09/839290

Inventors:

David Fick - Newport Beach CA, US
Mark Foreman - Tustin CA, US
Alvin Glasky - Tustin CA, US

International Classification:

C07D473/04

US Classification:

544/262000, 544/269000, 544/271000, 544/277000, 544/060000, 544/238000, 544/118000

Abstract:

A purine derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y)—D, where Ycan be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring and has two nitrogen atoms in the six-membered ring. The moiety A can be a purine moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

US Patent:

20030055249, Mar 20, 2003

Filed:

Jul 17, 2001

Appl. No.:

09/907273

Inventors:

David Fick - Newport Beach CA, US
Mark Foreman - Tustin CA, US
Alvin Glasky - Tustin CA, US

International Classification:

C07D417/02
C07D413/02
C 07D 4 3/02

US Classification:

544/060000, 544/122000, 544/295000, 544/238000, 544/328000

Abstract:

A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y)-D, where Ycan be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

US Patent:

20040116453, Jun 17, 2004

Filed:

Aug 25, 2003

Appl. No.:

10/648046

Inventors:

David Fick - Newport Beach CA, US
Mark Foreman - Tustin CA, US
Alvin Glasky - Tustin CA, US

International Classification:

A61K031/505
C 07D 4 3/02

US Classification:

514/275000, 544/330000, 544/331000

Abstract:

A pyrimidine derivative or analogue comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y)-D, where Ycan be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption, or promotes blood-brain barrier penetration of the derivative or analogue. The moiety A can have two or three nitrogen atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two nitrogen atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

US Patent:

20060182805, Aug 17, 2006

Filed:

Feb 14, 2006

Appl. No.:

11/353572

Inventors:

James Pfeiffer - Oakland CA, US
Mark Foreman - San Mateo CA, US
Michael Des Jardin - Sunnyvale CA, US
Janne Wissel - Sunnyvale CA, US
Samuel Saks - Burlingame CA, US

Assignee:

Jazz Pharmaceuticals - Palo Alto CA

International Classification:

A61K 31/4965
A61K 9/22
A61K 9/24

US Classification:

424468000, 424473000, 514255060

Abstract:

The invention is directed to a dosage form and method for administering a therapeutic agent in a sustained release manner to provide an intended therapeutic effect while minimizing the side effects associated with the therapeutic agent. The therapeutic agent is selected from a group of substituted pyrazine compounds and may be 3-(2,3,5-trichloro-phenyl)-pyrazine-2,6-diamine.

US Patent:

53867084, Feb 7, 1995

Filed:

Sep 2, 1993

Appl. No.:

8/115860

Inventors:

Huruli D. Kishorenath - San Jose CA
Johan E. de Rijke - Cupertino CA
Mark O. Foreman - Stockton CA

Assignee:

Ebara Technologies Incorporated - Santa Clara CA

International Classification:

B01D 800

US Classification:

62 555

Abstract:

Apparatus and method for vacuum pumping an enclosed chamber includes a cryogenic pumping device in fluid communication with the chamber for removing gases from the chamber. The cryogenic pumping device includes a cooled pumping surface and an expander for expanding a compressed gas and thereby cooling the pumping surface. The vacuum pumping apparatus further includes a sensor for sensing an operating parameter, such as temperature, of the cryogenic pumping device and a controller responsive to the sensor for controlling the operating speed of the expander to produce a desired value of the operating parameter. Typically, the sensor is a temperature sensor, and the controller controls the speed of the expander motor.